Peer-reviewed veterinary case report
Combretastatin A4-phosphate and its potential in veterinary oncology: a review.
- Journal:
- Veterinary and comparative oncology
- Year:
- 2017
- Authors:
- Abma, E et al.
- Affiliation:
- Department of Medicine and Clinical Biology of Small Animals
Plain-English summary
This article discusses a new approach to cancer treatment that goes beyond just attacking cancer cells. Researchers are exploring a type of drug called vascular disrupting agents (VDAs), which can help target the blood supply to tumors. One specific drug, combretastatin A4-phosphate (CA4P), is highlighted as a promising option for treating cancer in pets. The article also covers the possible side effects of CA4P in animals and how these side effects can be managed. Overall, the research aims to show how CA4P could be an effective cancer treatment for pets.
Abstract
For many years, research on anticancer therapy has focussed almost exclusively on targeting cancer cells directly, to selectively kill them or restrict their growth. But limited advances in this strategy have led researchers to shift their attention to other potential targets. Active research is now on-going on targeting tumour stroma. Vascular disrupting agents (VDAs) appear a promising class of anticancer drugs that are currently under investigation as a sole or combined therapy in human cancer patients. This article will briefly touch on the history and biology of combretastatin A4-phosphate (CA4P) as a typical example of VDAs and will concentrate on the side effects that can be expected when used in veterinary patients. Particularly, the pathogenesis of these side effects and how they may be prevented and/or treated will be discussed. The purpose of this article is to illustrate the potentials of CA4P as anticancer therapy in veterinary oncology patients.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/25988493/